EEG / EMG in Texas

Neurofeedback Supply and Equipment of Texas is the exclusive importer and distributor of the NeuronSpectrum line of EEG amplifiers in Texas. The company supplies clinical-grade EEG amplifiers (19–21 channel systems) for quantitative EEG (qEEG) analysis, clinical EEG recording, and neurofeedback training applications. Beyond equipment sales, the company provides comprehensive training and technical support to neurofeedback clinicians—both new and experienced—and assists mental health professionals in establishing brain-based clinical practices. They offer scalable solutions for small to large group practices, including staff selection, training, and practice development services.

Stratus (Alliance Neurodiagnostics, LLC) is a leading US provider of electroencephalography (EEG) solutions and services. The company delivers comprehensive end-to-end EEG services including ambulatory (at-home) video EEG testing, continuous EEG (cEEG) monitoring for ICU and epilepsy monitoring units (EMU), clinical trial support with decentralized and multi-site testing options, EEG hardware for inpatient and in-office use, and proprietary StratusEEG software for clinical workflow management and data analysis. Stratus serves thousands of clinicians across major U.S. healthcare systems, monitoring over 2 million patients remotely monthly and providing over 2.2 million hours of anonymized EEG data through their research division. The company integrates AI and deep learning algorithms to streamline EEG data analysis and support clinical decision-making without replacing clinician expertise. Stratus holds The Joint Commission accreditation and SOC 2 Type 2 certification, demonstrating commitment to quality and data security. The company is recognized as the #1 ambulatory EEG software provider in the United States and offers all-purpose EEG software in Scandinavia. Services extend to biomarker detection and research partnerships with leading healthcare organizations.

BrainCheck is a software platform for cognitive assessment and care planning, headquartered in Austin, Texas with operations in New York City. The company develops FDA-registered Class II digital cognitive assessment tools designed to integrate into clinical workflows for neurologists, psychiatrists, primary care providers, and clinical researchers. BrainCheck Assess, the platform's flagship product, is a 15-minute cognitive evaluation spanning five domains that detects subtle signs of cognitive impairment, potentially associated with dementias including Alzheimer's disease. The platform comprises 30+ clinical evaluation tools including validated screeners, assessments, and surveys. Published peer-reviewed research demonstrates that BrainCheck Assess scores correlate highly with the Montreal Cognitive Assessment (MoCA, r=0.77) and can distinguish between normal cognition, mild cognitive impairment, and dementia with high sensitivity and specificity. The platform supports seamless integration with major electronic health record systems (Epic, athenahealth) to enable cognitive screening, assessment, interpretation, care planning, and follow-up within routine care. BrainCheck's clinical validation is supported by a normative database of 5,000+ patients and real-world data from 450,000+ patient assessments. The company collaborates with leading academic and research institutions including University of Texas at Austin, Johns Hopkins University, Mount Sinai, Stanford University, and MD Anderson Cancer Center. U.S.-based clinical and technical support is available for product use, documentation, and billing inquiries.

Epiminder Limited develops and commercializes Minder®, an FDA-authorized implantable continuous EEG monitoring (iCEM®) system for long-term brain activity surveillance. The Minder system is designed to address diagnostic and management challenges in drug-resistant epilepsy by enabling continuous neural monitoring over months to years, compared to traditional scalp EEG monitoring limited to days. The implantable device allows patients to maintain normal daily activities while collecting high-quality EEG data, with remote monitoring capabilities to support clinical assessment and treatment planning. Epiminder targets neurologists and epilepsy centers managing patients with drug-resistant epilepsy, representing approximately 1.1 million adults in the US alone. The company emphasizes evidence-based innovation, clinical validation, and collaboration with the global epilepsy care community. Minder represents a significant advancement in seizure detection and neurological monitoring, extending the diagnostic window and providing actionable data to guide therapeutic interventions.

Mind Media Group manufactures and supplies EEG-based neurotechnology platforms for clinical, research, and educational applications. The company's core product line is the NeXus system—a multimodal biosensor platform available in wireless configurations (NeXus 10 MK3, NeXus Q24, NeXus Q32)—designed for nervous system sensing and real-time biofeedback/neurofeedback training. NeXus integrates EEG acquisition with sensors for physiological measurement (heart rate variability, skin conductance, respiration) and connects to Biotrace+, proprietary software for quantitative EEG (qEEG), biofeedback protocols, and neurofeedback applications. The platform serves three primary markets: clinical practice (mind-body assessments, therapeutic training for PTSD, ADHD, anxiety, depression), research (3000+ peer-reviewed publications), and education (certification and practitioner development). Complementary offerings include EEG caps, sensors, and cables. The company is widely adopted by major medical centers (Mayo Clinic, Cleveland Clinic, Kaiser Permanente), military and VA health systems (Walter Reed, multiple VA facilities, Department of Defense), academic institutions (MIT, Harvard, Max Planck Institute), and specialized centers (Rady Children's Hospital, Schön Klinik). Mind Media provides comprehensive training and education through its Path to Mastery Academy, offering courses from biofeedback basics through certified practitioner certification. The platform supports clinical assessment, performance optimization, and neuroscience research. Regulatory status, ISO certifications, and FDA classification status are not explicitly stated in available content.